The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer

Giorgio Bogani, Umberto Leone Roberti Maggiore, Biagio Paolini, Antonino Diito, Fabio Martinelli, Domenica Lorusso, Francesco Raspagliesi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To examine outcomes of patients having treatments for newly diagnosed advanced stage low-grade serous ovarian cancer (LGSC). Methods: We conducted a retrospective case series of women affected by advanced stage (stage IIIB or more) LGSC undergoing surgery in a single oncologic center between January 2000 and December 2017. Survival outcomes were assessed using Kaplan-Meier and Cox models. Results: Data of 72 patients were retrieved. Primary cytoreductive surgery was attempted in 68 (94.4%) patients: 19 (27.9%) had residual disease (RD) > 1 cm after primary surgery. Interval debulking surgery (IDS) was attempted in 15 of these 19 (78.9%) patients and the remaining 4 patients having not primary debulking surgery. Twelve out of 19 (63.1%) patients having IDS had RD. After a mean (±standard deviation) follow-up was 61.6 (±37.2) months, 50 (69.4%) and 22 (30.5%) patients recurred and died of disease, respectively. Via multivariate analysis, non-optimal cytoreduction (hazard ratio [HR]=2.79; 95% confidence interval [CI]=1.16-6.70; p=0.021) and International Federation of Obstetrics and Gynecologists (FIGO) stage IV (HR=3.15; 95% CI=1.29-7.66; p=0.011) were associated with worse disease-free survival. Via multivariate analysis, absence of significant comorbidities (HR=0.56; 95% CI=0.29-1.10; p=0.093) and primary instead of IDS (HR=2.95; 95% CI=1.12-7.74; p=0.027) were independently associated with an improved overall survival. Conclusion: LGSC is at high risk of early recurrence. However, owing to the indolent nature of the disease, the majority of patients are long-term survivors. Further prospective studies and innovative treatment modalities are warranted to improve patients care.

Original languageEnglish
Article numbere4
JournalJournal of Gynecologic Oncology
Volume30
Issue number1
DOIs
Publication statusPublished - Jan 2019

Fingerprint

Ovarian Neoplasms
Confidence Intervals
Multivariate Analysis
Survival
Proportional Hazards Models
Obstetrics
Disease-Free Survival
Survivors
Comorbidity
Patient Care
Prospective Studies
Recurrence
Therapeutics

Keywords

  • Cytoreduction surgical procedures
  • Drug therapy
  • Gynecologic surgical procedures
  • Neoplasm metastasis
  • Ovarian neoplasms

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

@article{2740ed385cc54e99bfe40b98ee6f9d68,
title = "The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer",
abstract = "Objective: To examine outcomes of patients having treatments for newly diagnosed advanced stage low-grade serous ovarian cancer (LGSC). Methods: We conducted a retrospective case series of women affected by advanced stage (stage IIIB or more) LGSC undergoing surgery in a single oncologic center between January 2000 and December 2017. Survival outcomes were assessed using Kaplan-Meier and Cox models. Results: Data of 72 patients were retrieved. Primary cytoreductive surgery was attempted in 68 (94.4{\%}) patients: 19 (27.9{\%}) had residual disease (RD) > 1 cm after primary surgery. Interval debulking surgery (IDS) was attempted in 15 of these 19 (78.9{\%}) patients and the remaining 4 patients having not primary debulking surgery. Twelve out of 19 (63.1{\%}) patients having IDS had RD. After a mean (±standard deviation) follow-up was 61.6 (±37.2) months, 50 (69.4{\%}) and 22 (30.5{\%}) patients recurred and died of disease, respectively. Via multivariate analysis, non-optimal cytoreduction (hazard ratio [HR]=2.79; 95{\%} confidence interval [CI]=1.16-6.70; p=0.021) and International Federation of Obstetrics and Gynecologists (FIGO) stage IV (HR=3.15; 95{\%} CI=1.29-7.66; p=0.011) were associated with worse disease-free survival. Via multivariate analysis, absence of significant comorbidities (HR=0.56; 95{\%} CI=0.29-1.10; p=0.093) and primary instead of IDS (HR=2.95; 95{\%} CI=1.12-7.74; p=0.027) were independently associated with an improved overall survival. Conclusion: LGSC is at high risk of early recurrence. However, owing to the indolent nature of the disease, the majority of patients are long-term survivors. Further prospective studies and innovative treatment modalities are warranted to improve patients care.",
keywords = "Cytoreduction surgical procedures, Drug therapy, Gynecologic surgical procedures, Neoplasm metastasis, Ovarian neoplasms",
author = "Giorgio Bogani and Maggiore, {Umberto Leone Roberti} and Biagio Paolini and Antonino Diito and Fabio Martinelli and Domenica Lorusso and Francesco Raspagliesi",
year = "2019",
month = "1",
doi = "10.3802/jgo.2019.30.e4",
language = "English",
volume = "30",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "1",

}

TY - JOUR

T1 - The detrimental effect of adopting interval debulking surgery in advanced stage low-grade serous ovarian cancer

AU - Bogani, Giorgio

AU - Maggiore, Umberto Leone Roberti

AU - Paolini, Biagio

AU - Diito, Antonino

AU - Martinelli, Fabio

AU - Lorusso, Domenica

AU - Raspagliesi, Francesco

PY - 2019/1

Y1 - 2019/1

N2 - Objective: To examine outcomes of patients having treatments for newly diagnosed advanced stage low-grade serous ovarian cancer (LGSC). Methods: We conducted a retrospective case series of women affected by advanced stage (stage IIIB or more) LGSC undergoing surgery in a single oncologic center between January 2000 and December 2017. Survival outcomes were assessed using Kaplan-Meier and Cox models. Results: Data of 72 patients were retrieved. Primary cytoreductive surgery was attempted in 68 (94.4%) patients: 19 (27.9%) had residual disease (RD) > 1 cm after primary surgery. Interval debulking surgery (IDS) was attempted in 15 of these 19 (78.9%) patients and the remaining 4 patients having not primary debulking surgery. Twelve out of 19 (63.1%) patients having IDS had RD. After a mean (±standard deviation) follow-up was 61.6 (±37.2) months, 50 (69.4%) and 22 (30.5%) patients recurred and died of disease, respectively. Via multivariate analysis, non-optimal cytoreduction (hazard ratio [HR]=2.79; 95% confidence interval [CI]=1.16-6.70; p=0.021) and International Federation of Obstetrics and Gynecologists (FIGO) stage IV (HR=3.15; 95% CI=1.29-7.66; p=0.011) were associated with worse disease-free survival. Via multivariate analysis, absence of significant comorbidities (HR=0.56; 95% CI=0.29-1.10; p=0.093) and primary instead of IDS (HR=2.95; 95% CI=1.12-7.74; p=0.027) were independently associated with an improved overall survival. Conclusion: LGSC is at high risk of early recurrence. However, owing to the indolent nature of the disease, the majority of patients are long-term survivors. Further prospective studies and innovative treatment modalities are warranted to improve patients care.

AB - Objective: To examine outcomes of patients having treatments for newly diagnosed advanced stage low-grade serous ovarian cancer (LGSC). Methods: We conducted a retrospective case series of women affected by advanced stage (stage IIIB or more) LGSC undergoing surgery in a single oncologic center between January 2000 and December 2017. Survival outcomes were assessed using Kaplan-Meier and Cox models. Results: Data of 72 patients were retrieved. Primary cytoreductive surgery was attempted in 68 (94.4%) patients: 19 (27.9%) had residual disease (RD) > 1 cm after primary surgery. Interval debulking surgery (IDS) was attempted in 15 of these 19 (78.9%) patients and the remaining 4 patients having not primary debulking surgery. Twelve out of 19 (63.1%) patients having IDS had RD. After a mean (±standard deviation) follow-up was 61.6 (±37.2) months, 50 (69.4%) and 22 (30.5%) patients recurred and died of disease, respectively. Via multivariate analysis, non-optimal cytoreduction (hazard ratio [HR]=2.79; 95% confidence interval [CI]=1.16-6.70; p=0.021) and International Federation of Obstetrics and Gynecologists (FIGO) stage IV (HR=3.15; 95% CI=1.29-7.66; p=0.011) were associated with worse disease-free survival. Via multivariate analysis, absence of significant comorbidities (HR=0.56; 95% CI=0.29-1.10; p=0.093) and primary instead of IDS (HR=2.95; 95% CI=1.12-7.74; p=0.027) were independently associated with an improved overall survival. Conclusion: LGSC is at high risk of early recurrence. However, owing to the indolent nature of the disease, the majority of patients are long-term survivors. Further prospective studies and innovative treatment modalities are warranted to improve patients care.

KW - Cytoreduction surgical procedures

KW - Drug therapy

KW - Gynecologic surgical procedures

KW - Neoplasm metastasis

KW - Ovarian neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85058874431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058874431&partnerID=8YFLogxK

U2 - 10.3802/jgo.2019.30.e4

DO - 10.3802/jgo.2019.30.e4

M3 - Article

C2 - 30479088

AN - SCOPUS:85058874431

VL - 30

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 1

M1 - e4

ER -